ERBB2 and non-small cell lung carcinoma: We hypothesised that HER2 overexpression can drive therapeutic resistance in EGFR mutated NSCLC patients treated with EGFR TKIs and that these patients may benefit from treatment with trastuzumab-paclitaxel.